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Effect of experimental diabetes on insulin binding by renal basolateral
membranes. Removal of insulin from the perituhular vessels involves
binding of insulin to specific receptors in the basolateral membranes
(BLM); this is followed by phosphorylation of the receptor which may
mediate the actions of the hormone. In most tissues receptor number is
regulated by plasma insulin levels and is increased in insulinopenic
diabetics. To determine whether cortical BLM insulin receptors are
similarly regulated, we studied insulin binding to receptors in BLM
from normal control rats and rats with streptozotocin diabetes of
varying severity. Specific binding of insulin did not differ between
control and modestly insulinopenic diabetics but was increased signif-
icantly in the severely insulinopenic diabetics. Insulin treatment re-
turned binding to normal. Scatchard analysis suggested an increase in
the binding capacity of the severe diabetic BLM rather than an increase
in affinity for insulin. This latter was confirmed by competitive exper-
iments in which similar displacement curves were obtained with control
and diabetic membranes. Insulin removed by glomerular filtration binds
to specific receptors in the luminal membranes but unlike BLM recep-
tors, phosphorylation of these luminal receptors has not been observed.
To determine whether luminal and BLM receptors differ structurally,
binding sites in both membranes were affinity labelled with '251-insulin
and the cross linking agent, disuccinimidyl suberate, and subjected to
SDS-polyacrylamide gel electrophoresis in the presence of a reducing
agent. Autoradiograms revealed that the major specifically labelled
subunit in both membranes is a 135,000 Mr species which is more
abundant in the BLM. We conclude that insulin receptors in cortical
BLM respond to severe insulinopenic diabetes as do receptors in most
other tissues. Furthermore, it appears that the a subunit structure of
basolateral and luminal membrane receptors are similar and do not
differ from insulin receptors in most tissues.
The relationship between the kidney and insulin is complex,
for in addition to being a major site of insulin removal and
degradation, the kidney is a target for several of the hormone's
actions. These actions include stimulation of sodium, potassium
and phosphate reabsorption and regulation of metabolic events
[1—31. To initiate action, binding of insulin to its specific
receptor is required. Although non-receptor mediated degrada-
tion does occur, receptor binding is usually a prerequisite for
degradation [41. In the kidney, insulin—specific receptors have
been identified in glomeruli and in purified cortical luminal and
basolateral membranes [5—7 1. It is likely that the luminal recep-
tors play a primary role in absorption and hence degradation of
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insulin, while basolateral membrane receptors are more likely
concerned with the hormone's actions [81. This concept is
supported by the finding that insulin stimulates phosphorylation
of its receptor in basolateral but not brush border membranes
[91; it is presumed that phosphorylation may serve in mediating
the hormone's action [321. In most tissues the number of plasma
membrane insulin receptors is inversly related to the ambient
insulin concentration. Thus, for example, in obesity associated
with hyperinsulinemia, adipose tissue, liver, and monocytes
show a significant decrease in receptor number [10, iii, while in
insulin deficient diabetes receptor number is increased [12, 13].
An exception is the brain, a tissue which does not appear to
regulate receptor number [14, 151.
In this study we set out, first to determine whether there is
regulation of insulin—receptor binding by purified renal cortical
basolateral membranes (BLM), and second to determine
whether the functionally distinct luminal and BLM receptors
also differ in respect to their subunit structure. To achieve the
first goal, we have compared binding of insulin by BLM isolated
from normal rats with that of rats with streptozotocin—induced
diabetes of varying severity and found that receptor number
increased only in the most severe form of diabetes. To achieve
the second goal, we have examined the a subunit of the insulin
receptor in luminal and BLM after covalent cross linking of
'251-insulin to the membranes and then subjecting them to
SDS-polyacrylamide gel electrophoresis (PAGE) in the pres-
ence of a reducing agent. The a subunit of the receptors from
these two sites were similar anti were comparable to insulin
receptors in other tissues.
Methods
Materials
A14 human and B26 pork [12511 monoiodoinsulin was pre-
pared as previously described [16]. The advantage of these
tracers are that they are relatively stable, and retain both
receptor binding properties and bioactivity. '251-salmon
calcitonin with less than one iodine atom per molecule (0.8) was
prepared by a modification of the chloramine T method [17].
Hormone from this species was used as it retains full bioactivity
when monoiodinated with chloramine T [181. Bovine serum
albumin (BSA) fraction V, essentially fatty acid free, was
obtained from Miles Laboratories, Inc., (Elkhart, Indiana,
USA) and Percoll from Pharmacia, Inc. (Piscataway, New
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Table 1. Biochendcal profile and wcight at time of sacrifice
Plasma Plasma
No. glucose insulin
rats Wt. g mg/dl U/ml
Control 31 348 168
--2
59
Moderate diabetes 38 344 406 32
Severe diabetes 28 281 712 8
Treated diabetes 27 328 392 37
Jersey, USA). The following items were gifts; porcine insulin,
proinsulin and glucagon (Eli Lilly & Co., Indianapolis, Indiana,
USA), streptozotocin (Upjohn Co., Kalamazoo, Michigan,
USA), rat growth hormone (NIADDK), synthelic salmon
calcitonin (Armour Pharmaceutical Co., Kankakee, Illinois,
USA).
Animals
Male Sprague—Dawley rats (Simonsen and Co., Gilroy, Cal-
ifornia, USA) weighing 300 to 400 g were used in this study.
Free access to food and water was allowed throughout. Four
groups of rats were studied. Group I were normal control rats,
group II consisted of rats with moderate diabetes induced by
the injection of streptozotocin (STZ), 55 mg/kg intravenously,
group III were severely diabetic rats who had received STZ 75
mg/kg, and group IV consisted of diabetic rats (STZ 75 mg/kg)
maintained throughout the study on insulin. Forty—eight hours
after the injection of STZ, all diabetic rats were placed on
insulin --3 U/day subcutaneously, for seven days. Therapy was
then withdrawn from group 11 and III rats, but continued in
group IV. Rats were sacrificed seventeen to twenty—one days
after receiving STZ. Renal cortices from six to eight rats were
pooled and placed in 8% sucrose wt/wt and homogenized with
10 strokes of a B pestle in a Dounce homogenizer. Isolated
basolatcral membranes (BLM) and luminal membranes were
prepared from the homogenates by a modification of the method
of Kinsella et al [191 and involves differential centrifugation,
cationic precipitation, and centrifugation on a Percoll gradient.
Fractions crudely enriched in BLM were separated from
luminal membranes as described by these authors except that a
10 m cation containing solution (5 rnrvt MgCI2 and 5 mrvi CaCI2)
was used. After separation of the luminal membranes from the
crude BLM precipitate, both fractions were dialysed overnight
as described by Kinsella ci a! [19] to remove the excess of
cations. Basolateral membranes were then purified by centrif-
ugation on an 11% Percoll gradient for 35 minutes at 48,000 g.
Percoll was suspended in 0.25 M sucrose containing 1 mM
EDTA and 10 rnrvt Tris at pH 7.4. The purified hasolateral
membranes were separated from Percoll by first diluting the
sample with Krebs Ringers Tris buffer followed by centrifuga-
tion at 218,000 g for 40 minutes and gently washing the
membranes off the hard Percoll pellet. The membranes were
then resuspended in 30 ml Krehs Ringers 'Iris buffer and
centrifuged for 21) minutes at 40,000 g. This final pellet was used
in the binding assays.
Binding Assays
These were performed, with few modifications, as previously
described [71. Isolated BLM, 50 .tg of protein was incubated at
pH 7.4 in 100 1.d of Krebs Ringers Tris buffer containing 0.5%
bovine serum albumin (BSA), A14 [I] insulin (1.7 x 10_b0 M)
and 1 mist N-ethylmaleimide (NEM) in the presence or absence
of unlabelled hormone. Incubations were performed at 22°C for
90 minutes in triplicate. Following incubation, membrane
bound and free insulin was separated by filtering and washing
under negative pressure on BSA-coated cellulose acetate filters
(Sartorius, 0.2 gm). The wash consisted of 6 ml cold Krebs
Ringers Tris buffer with 0.1% BSA. Under the conditions of the
study specific binding of '291-insulin to BLM at 90 minutes did
not differ significantly from binding at 180 minutes. Binding was
proportional to membrane protein concentration over the range
25 to 75 p,g/l00 d. Similar findings were observed with mem-
branes from diabetic rats. In the presence of NEM degradation
was less than 1% of the radioactivity added, and no correction
for degradation was made. Nonspecific binding measured in the
presence of 10 M cold insulin was <0.4%, and was used to
determine specific binding. When binding to luminal membrane
was studied, 75 ,ug of protein was used and the membranes
incubated for 120 minutes. Over the range 50 to 125 g/l00 l
binding was proportional to membrane protein concentration.
Binding was corrected for degradation, which was —3% of the
radioactivity added. Degradation was measured by the appear-
ance of radioactivity soluble in trichloroacetic acid, final con-
centration 6% [81.
Affinity labelling qfinsulin receptor
Luminal and BLM were incubated with Al4 or B26 [I2I]
insulin (1.7 X 10 M) as described above. Two concentrations
of membrane proteins were used. 50 and 200 jg/l00 sl. After
120 minutes, the membranes were separated from the incuba-
tion buffer by centrifugation and resuspended in phosphate
buffered saline to which the cross—linking agent disuccinimidyl
subcrate (0.5 mM) was added [201. The membranes were then
solubilized and reduced in 1% SDS and 5% mercaptocthanol,
heated for 1 mm at 100°C and electrophoresed on a 7.5%
SDS-polyacrylamide gel [2 I]. 'l'he gels were stained, destained,
dried, and autoradiographed with the usc of DuPont Eronex
Lightening—Plus intensifying screens (Wilmington, I)claware,
USA). Molecular weights wcrc determined by comparison with
the following standards: myosin (200,000), p-galactosidase
(ll6,000), phosphorylase h (92,500), bovine serum albumin
(66,200), and ovalbumin (45,000).
291-was counted in a Beckman 4000 gamma counter (Beck-
man Instruments, Fullerton, California, USA). Protein was
determined by the method of Lowry et al [221. The following
marker enzyme activities were measured: Na-K-ATPase 1231,
acid and alkaline phosphatase [241. cytoehrome-c reductase
1251, and succinate dehydrogenase 1261 Plasma insulin levels
were measured by radioimmunoassay [271, and glucose with a
Beckman glucose analyzer. The results were expressed as the
mean SEM and were statistically analyzed with a one—way
analysis of variance. If the F ratio was significant, Duncans
multiple range test was used to make comparisons between the
groups. A level of P < 0.05 was regarded as significant.
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Table 2. Enrichment of marker enzyme activity of basolateral membrane (BLM) prcparation relative to homogenate
Group Na-K-ATPase
Alkaline
phosphatase
NADPH cyto. c
reductase
Acid
phosphatase
Succinate
dehydrogenase
BLM control (4) 16.6 0.7 2.4 0.5 2.0±0.3 0.7 0.07 0.2 0.02
Moderate diabetic (4) 14.3 1.3 2.7 0.5 2.4 0.3 0.9 0.20 0.3 0.02
Severe diabetic 18.5 2.6 3.0 0.4 2.1 0.3 0.5 0.03 0.2 0.03
Treated diabetic 5.2 2.2 3.1 0.3 1.3 0.3 0.7 0.03 0.5 0.07
Moderate Severe Treated
diabetea diabetes diabetes
N=4 5 4 3
Fig. 1. Percent insulin specificollv bound to renol corticol bosolaterol
,ne,'nbrones from control nod thohetic rots meosored ot physiologicol
insulin conceotrotions (1.7 x 10'° M). Binding was performed in
triplicate, and was carried out with membranes pooled from six to eight
rats. Each tube contained 50 jzg membrane in 100 j.d incubation buffer.
The number of pools per group is indicated on the figure. Data expresed
as mean 5EM (5P < 0.05).
Results
Characteristics of animals and isolated plasma membranes
The weight, plasma glucose, and insulin levels of the rats at
time of sacrifice are shown in Table 1. Plasma glucose levels
were elevated in all the diabetic groups, being highest in the
untreated severe diabetics. Plasma insulin levels were signifi-
cantly depressed in the diabetics, and as anticipated were
lowest in the severe diabetics. Maintenance insulin treatment of
rats who received the maximum dose of STZ used, group IV,
was associated with plasma glucose and insulin levels similar to
the moderate diabetics.
The enrichment of the isolated BLM preparations when
compared to crude homogenate is shown in Table 2. In the
controls, the activity of the BLM marker enzyme was enriched
sixteenfold relative to the homogenate. Contamination with
other cellular components was low. Relative enrichment of
marker enzyme activity was similar in the four study groups.
However, there were differences in the specific activity of
Na-K-ATPase in cortical homogenates and in the purified
BLMs. Cortical Na-K-ATPase activity was significantly in-
creased in the severe diabetic and treated diabetic groups when
compared to controls (6.4 0.67 and 5.7 0.52 versus 3.9
0.07 rmo1/mg protein/hr respectively; P < 0.05). Although on
Native hormone
(l06M)
Total
(9(
251-insu
control
lin bound
value)
Zero (control) 100
tnsulin 7.6 0.6
Glucagon 90.9 2.0
Calcitonin 98.8 1.4
Growth hormone 95.4 2.3
Somatostatin 98.6 3.0
average higher than the control values, enzyme activity in the
moderate diabetics (5.1 0.42 rmol/mg/hr) did not differ
significantly from the controls. Similar changes were observed
with the isolated BLM. Na-K-ATPase activity in control,
moderate diabetics, severe diabetics and treated diabetics av-
eraged 64.7 2.53, 70.3 1.97, 113 4.72 and 84.4 3.54
mol/mg protein/hr, respectively. The value obtained in the
severe diabetic group was significantly higher than in the other
three groups (P < 0.01). Although the Na-K-ATPase activity in
the treated diabetics was lower than in the severe diabetics, it
was higher than in the control (P < 0.01). Luminal membranes
from control animals were enriched eightfold relative to
homogenate in respect to the luminal marker enzyme alkaline
phosphatase, and 0.3-fold with respect to Na-K-ATPase.
The percentage of '251-insulin specifically bound by BLM
from control and diabetic rats at physiological insulin concen-
trations is shown in Figure 1. Specific binding by membranes
from the control and moderate diabetic group was similar and at
the physiologic concentration studied (1.7 x 10°° M) averaged
16 0.7 and 18 1.9 fmol/mg protein, respectively. Severe
diabetes was associated with significantly more binding, 28
4.5 fmol/mg, than the control or moderate diabetic groups.
Treatment with insulin lowered '251-insulin binding to a value of
19 1.3 fmol/mg, which did not differ from the controls.
To confirm that binding of 125l-insulin to BLM is insulin—
specific, the inhibitory effect of an array of non-insulin peptides
was examined (Table 3). (ilucagon, calcitonin, growth hor-
mone, and somatostatin in concentrations of 10-6 M were
relatively ineffective in inhibiting binding when compared to
insulin. Binding of '251-insulin to BLM and luminal membranes
isolated from the same three pools of control rats was also
compared. At physiologic insulin concentrations (1.7 x
10-10 M), luminal membranes bound significantly less insulin
than BLM (6 0.7 vs. 16 0.8 fmol/mg protein).
When BLM were exposed to increasing concentrations of
native insulin, 10° to 10—6 M, the severe diabetic group bound
more insulin than the control at each concentration (Fig. 2).
This reached significance at all except the highest insulin
concentration tested. These findings indicate that in severe
10
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4
2
C
0
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Table 3. Effect of various peptide hormones on '25l-insulin binding to
basolateral membranes
Three BLM preparations were incubated with 25l-insulin (1.7 ><
l0'°M) and the various hormones listed.
Insulin concentration, log M
Figure 2. Total amount of insulin specifically hound to bosnia/era!
membranes from control and diabetic rats or carving insulin cOflCen—
trahons, Mean siu. (*p, 0.05; 'P < 0.01). Symbols are: (0)
control, N 4; (x) moderate diabetes, N = 5: (•) severe diabetes,N 4.
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diabetes, BLM increases their capacity to bind insulin. By
contrast, binding by BLM from the moderate diabetic group did
not differ from that of controls. It is noteworthy that continued
insulin therapy of rats who received maximum doses of STZ
(group IV) was associated with normalization of BLM insulin
binding (Fig. 3). At all concentrations tested, binding of 25l
insulin to BLM from these treated diabetics was significantly
less than that of the severe diabetics. The same dose of STZ
was used to induce diabetes in these two groups of rats.
Results of the competition for binding between '251-insulin
and increasing concentrations of native insulin are shown in
Fig. 4. The competitive displacement curves obtained with the
control, moderate and severe diabetic groups were similar.
These displacement curves were used to determine the concen-
tration of native insulin at which 1251-insulin hound was 50%of
maximum. For the controls and moderate diabetics this aver-
aged 2.7 nM, and for the severe diabetics 3 n. These findings
strongly suggest that receptor affinity for insulin was similar in
the three groups.
The data obtained from the competitive binding experiments
with native and 251-insulin was subjected to Seatchard analysis
[281. The results from the control and severe diabetic groups are
plotted in Figure 5. Both the control and the diabetic curves are
curvilinear, which is consistent with two or more classes of
receptors with different capacities and affinities, or with the
presence of a single class of receptors with a negative co-
operative type of hormone receptor interaction [291. The curve
obtained with the severe diabetics is essentially parallel to the
control curve; but is displaced upwards. This indicates, as does
Figure 4, that the insulin binding affinities of the control and
severe diabetic membranes are similar and that the difference in
insulin binding is due to an increase in receptor number. To
exclude the possibility that the increase in insulin binding might
be due to a non-specific effect of the diabetic state, binding of
1251-salmon calcitonin to BLM prepared from control and
severely diabetic rats was examined. Specific binding of
calcitonin at physiological concentrations (0.5 x 10° si) to
BLM averaged 20.7 1.4%/ISO g protein for controls and 16.4
2.5% for severe diabetics.
The subunit structures of the BLM and luminal membrane
insulin receptors were examined by electrophoresis on reduced
SDS-polyacrylamide gels after covalently attaching B26 or A14
[1251] insulin to the receptor with the hifunctional cross—linking
agent, disuccinimidyl suherate [30]. Autoradiograms depicting
the structures of the covalently labelled BLM and luminal
membrane insulin receptors arc shown in Figure 6. In both
membranes the major specifically labelled subunit with the
cross—linker is a 135,000 Mr species. Although both membranes
were exposed to the same insulin concentration, labelling of the
BLM was more intense, in keeping with the greater abundance
of receptors in BLM than luminal membranes [6, 91. Further-
more, labelling with B26 [12)1] insulin was more effective than
with Al4 [1251] insulin (data not shown), confirming the finding
of Heidenreich et al [20] in adipocytes. This phenomenon is
probably a consequence of reduction of the bond between the ct
and f3 chain which is covalently linked to the insulin receptor,
hence the decrease in radioactivity with a chain labelled insulin.
Discussion
In the first part of this study carried out with normal and STZ
diabetic rats, we set out to determine whether binding of insulin
by renal cortical hasolateral membranes is a regulated process.
NS
**
**
40
30
20
10
5
3
2
0.8
0.6
C
'I)
C
C.
a
c
0
-o
>
(0a
"a
a)0.
a)
C
C0C
40
30
20
10
5.
NS
///
**
,
*
I
**
*
—10 -9 -8 -7
C
0)
C
C.
C.
a.
0C00
.0
.. 3.
a)U
' 2'
a)0.
0,
C
C
a) 1C
0.8
Figure 3. Total amount qf insulin .specficallv bound to ba.solateral
membranes from 'on/rn! rats, rots m'it/j severe diabetes, and rat,v with
treated diabetes. Mean scsi. OP 0.05: P < 0.01). Symbols are:
(0) control, N = 4: (I) severe diabetes, N = 4 and (A) treated
diabetes, N 3.
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Figure 4. (oFnpetitire inhibition of '251—jnsuljn binding to hasolareral
,ne,nbranes obtained from control and se'e,elv diabetic rats. Various
concentrations of native insulin were added to membranes incubated
with 1.7 x 10 vi 251-insulin. Symbols are: (0) control. N 4: (S)
severe diabetes, N = 4.
Insulin specifically bound, fmz50 og protein
Figure 5. Scatchard analysis of data presented in Figure 4. Symbols
arc the same as Figure 4.
Figure 6. Covalent cross—linking of '251-ins u/in to the insulin receptors
of BLM and luminal membranes. Two hundred g of either BLM (lanes
A,B) or luminal membranes (lanes C,D) protein were incubated with 1.7
nM of B26 [12511 insulin in the presence (lane A,C) or absence (lanes
B,D) nfl ,LLM unlabeled insulin. After two hours at 22°C, the membranes
were pelleted, cross—linked, solubilized, and electrophoresed on SDS
gels as described in methods. An autoradiograph of the gel is shown.
Specific binding of B26 [05J] insulin was measured in parallel tubes.
Basolateral membranes bound 6.4% and luminal membranes I .5%f200
pg protein at a 1251-insulin concentration of 1.7 nra.
binding to control values, thus excluding the possibility that the
altered binding might be related to a direct renal action of STZ.
It is noteworthy that moderate diabetes, (average blood glucose
450 mg/dl and serum insulin 32 rU/ml), was not accompanied
by significant changes in insulin binding. 1hese findings are
similar to those reported with isolated hepatic plasma mem-
branes [13]. To determine whether the increase in binding was
due to a change in receptor affinity for insulin, we compared
competitive binding experiments performed with membranes
from severely diabetic rats to experiments performed with
normal control membranes and found that the competitive
binding curves were similar (Fig. 4). The 50% maximal binding
capacity, a measure of relative receptor affinity, was estimated
from these curves and the value for the control and severe
diabetic membranes were 2.7 and 3 nM insulin, respectively.
This finding argues against an alteration in receptor affinity and
leads to an examination of receptor number. Use of Scatchard
analysis to determine the exact number of receptors present in
a complex binding system is fraught with error [28], neverthe-
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less it is still useful to compare the plots obtained by (his
analysis. By examining Figure 5, it is apparent that relative to
the control curve, the diabetic curve is parallel and displaced
upwards, with the diabetic curve intercepting the abscissa at a
higher insulin concentration than the control curve. These
findings again indicate that receptor affinity is unaltered by
severe diabetes, but also suggest that receptor number is
increased. This is consonant with the diabetes associated
changes in insulin receptors noted in other tissues [12, 13]. The
mechanism accounting for the increase in number of renal
tubular BLM insulin receptors in the severely diabetic state and
the biological significance thereof requires consideration.
In general, the number of insulin receptors in cell membranes
are determined by several different agents and physiological
states [31. 32]. A major determinant is the ambient insulin
concentration, and a change in insulin concentration is followed
by an opposite change in receptor number [331. Thus in the
severe untreated diabetic rats described, it is likely that the low
circulating insulin levels are an important determinant of the
increase in BLM receptor number. In the moderate diabetics,
the decrease in serum insulin concentration may have been too
small to produce a discernable effect on receptor binding. While
in the treated diabetic the insulin levels achieved, although
insufficient to adequately control the hyperglycemia, were
sufficient to return the BLM insulin binding to the control
range. Other metabolic and endocrine alterations occur in the
diabetic state, such as ketosis and hypersecretion of glucagon,
growth hormone, and glucocorticords, and may also influence
the receptor number [31, 321. The exact contribution of each of
these factors to the change in BLM insulin binding is unclear. In
order to exclude the possibility that the increase in insulin
binding might be due to a non-specific effect of the diabetic
state, particularly in light of the increase in BLM Na-K-ATPase
activity, we measured the binding of an unrelated peptide,
salmon calcitonin, to isolated BLM membranes from severely
diabetic rats, At the physiological concentration of calcitonin
studied there was no increase in binding to the diabetic mem-
branes. This finding supports the notion that the increase in
BLM insulin binding in diabetes is specific for this hormone.
The increase in Na-K-ATPase activity in the severe diabetic
rats is of interest and has recently been described by other
workers [34, 35] who suggested that this may represent an
adaptive response to an increase in the filtered load of sodium
and the excessive sodium loss that accompanies uncontrolled
diabetes, According to Ku and Meezan [341, the increase in
Na-K-ATPase activity appears to be due to an increase in the
number of Na-K-ATPase pump sites.
Regulation of' receptor number is a mechanism which serves
to modify the response of the cell to circulating insulin [32].
However, the biological significance of an increase in receptor
number in tubular BLM of severely diabetic rats is at present
speculative. Normally, binding of insulin to its specific receptor
triggers one or more signaling mechanisms which culminates in
the biological action of the hormone. In the uncontrolled
diabetic state where sodium and phosphate wastage occurs, an
increase in receptor number would seem advantageous, for this
may permit the more efficient utilization of circulating insulin to
stimulate sodium and phosphate reabsorption [1, 2]. However,
it should be remembered that cellular metabolism is altered in
diabetes and defects in events subsequent to binding may
occur. Hence binding of' hormone to receptor may not be
translated into the expected action. Such defects in cellular
response to insulin are present in other tissues hut have yet to
be evaluated in the kidney [12, 31].
It is now well established that there are also receptors for
insulin in cortical luminal membranes [6, 9], albeit at a lower
concentration than in the BLM [9]. Exposure of both these
membranes to insulin is followed by phosphorylation of the
BLM hut not the luminal membrane receptors [91. This favors
the thesis that BLM insulin receptors play a role in mediating
the hormone's action, whereas luminal receptors serve a role in
the specific absorption and eventual degradation of insulin [8].
In the second part of this study we set out to determine whether
the anatomically distinct BLM and luminal membrane receptors
also differ structurally. Before discussing these findings, it
should be useful to briefly outline the known structure of the
insulin receptor [31, 32]. This receptor is a heterotetrameric
disulphide linked glycoprotein which consists of two a and two
13 units. The a subunit appears to contain the hormone binding
sites while the f3 subunit appears related to action, for it has
intrinsic tyrosine kinase activity and is readily phosphorylated
in the presence of insulin. Phosphorylation of the insulin
receptors presumably plays a role in transmitting signals from
the hormone to its final site of action. Apart from the brain,
which has insulin receptors which differ structurally from those
of other tissues [36], the typical insulin receptor has a mass of
430,000 with an a subunit mass of 135,000 [31, 321. In the
present study, the a subunit structure of the insulin receptor in
tubular luminal and BLM was examined by affinity cross—link-
ing B26['2511 insulin to the insulin receptor, followed by SDS-
polyacrylamide gel electrophoresis in the presence of a reduc-
ing agent. One major labelled band of Mr 135.000 was specifi-
cally labelled in both membranes; this band was more promi-
nent in the BLM (Fig. 6). These findings indicate that insulin
receptors are more plentiful in the BLM and that there are no
major differences between the a subunit mass of the luminal and
BLM insulin receptors and that of the typical insulin receptor in
other tissues. Analysis does not preclude less obvious struc-
tural differences between the a subunits of the receptors. The
structure of the p subunit was not examined, but the observa-
tion by Hammerman and Gavin [9] that insulin does not
stimulate phosphorylation in luminal membranes suggests to us
that differences in this subunit may exist. In recent publications
these workers [37, 38] reported that the a subunits of the insulin
receptor in luminal and BLM from the dog kidney also have a
Mr of 135,000; findings similar to our observations in the rat.
In summary, the present study in rats with chemical induced
diabetes demonstrates that insulin receptors in renal cortical
BLM respond to environmental changes as do insulin receptors
in most other tissues. We observed that severe insulinopenic
diabetes is accompanied by an increase in insulin binding to
BLM, apparently due to an increase in receptor number, while
receptor affinity remains unchanged. In addition, this study
revealed that the a subunit structure of BLM and luminal
membrane insulin receptors are similar and do not appear to
differ from that reported in other tissues.
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